Novo India has slashed the price of its growth hormone therapy, Norditropin FlexPro, by up to 35% to support adults and children living with growth hormone deficiency (GHD) across the country. Effective immediately, the company has introduced a new India-specific pricing model for both the 10 mg and 15 mg dose strengths, making this innovative treatment significantly more accessible.

The price of the 10mg device has been reduced by 33%, from Rs. 16,836 to Rs. 11,300, while for 15mg device price has been reduced by 35%, from Rs. 25,254 to Rs. 16,450 — translating to savings of Rs. 5,539 and Rs. 8,802 per pen, respectively.

This significant step is part of Novo's continued commitment to expanding access and affordability to essential therapies for people living with growth hormone deficiency and related conditions across India.

Vikrant Shrotriya, Managing Director, Novo India said, "Growth hormone deficiency is a rare endocrine disorder, with published estimates suggesting it affects approximately 1 in 4,000 to 1 in 10,000 children. At Novo India, we are committed to deliver innovation and ensure that every child living with growth hormone deficiency has access to the therapy they need. This price reduction is a direct reflection of that commitment and reinforces our long-term focus on enabling life-changing treatment to reach children and families across India."

Growth hormone deficiency happens when the pituitary gland fails to make enough growth hormone for normal development. While it can be present from birth or develop over time due to genetic factors, brain structure issues, or pituitary damage, the exact cause remains unknown for many children.

Norditropin FlexPro is a pre-filled, easy-to-use growth hormone pen designed for children requiring long-term therapy. The device is designed to support ease of use and adherence for youngsters and their caregivers managing a long-term treatment journey.